An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”

BMC Infectious Diseases

Maarten J Postma¹  Albert C Noort¹  Pieter T de Boer¹  Mark H Rozenbaum¹  Hong Anh T Tu¹ 

[1] Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada

关键词: the Netherlands;    Rotavirus vaccination;    Cost-effectiveness analysis;   

Others  :  1158468
DOI  :  10.1186/1471-2334-13-54

 received in 2012-07-23, accepted in 2013-01-17,  发布年份 2013

【 摘 要 】

Background

To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.

Methods

The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.

Results

When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92–122, depending on the applied threshold.

Conclusions

We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.

【 授权许可】

   
2013 Tu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ: Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011, 11:462. BioMed Central Full Text
• [2]Bruijning-Verhagen P, de Waal W, Winkel L, Felderhof M, van Houten M, Thijsen S, et al.: Rotavirus related hospitalizations: Incidence and contribution to seasonal peaks in pediatric hospital admissions. Thessaloniki, Greece: Poster at ESPID-conference 2012; 2012.
• [3]Friesema IH, De Boer RF, Duizer E, Kortbeek LM, Notermans DW, Norbruis OF, et al.: Etiology of acute gastroenteritis in children requiring hospitalization in the Netherlands. Eur J Clin Microbiol Infect Dis 2012, 31:405-415.
• [4]de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Bartelds AI, van Duynhoven YT: Gastroenteritis in sentinel general practices, The Netherlands. Emerg Infect Dis 2001, 7:82-91.
• [5]de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van LF, et al.: Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol 2001, 154:666-674.
• [6]Mangen MJ, van Duynhoven YT, Vennema H, Van PW, Havelaar AH, de Melker HE: Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010, 28:2624-2635.
• [7]Zomer TP, van Duynhoven YT, Mangen MJ, van der Maas NA, Vennema H, Boot H, et al.: Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008, 26:3757-3764.
• [8]Glass RI: Unexpected benefits of rotavirus vaccination in the United States. J Infect Dis 2011, 204:975-977.
• [9]de Wit MA, Koopmans MP, van der Blij JF, van Duynhoven YT: Hospital admissions for rotavirus infection in the Netherlands. Clin Infect Dis 2000, 31:698-704.
• [10]Goossens LM, Standaert B, Hartwig N, Hovels AM, Al MJ: The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008, 26:1118-1127.
• [11]Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al.: The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128.
• [12]Lopman BA, Curns AT, Yen C, Parashar UD: Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204:980-986.
• [13]Atkins KE, Shim E, Pitzer VE, Galvani AP: Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30:552-564.
• [14]Van ET, Soriano-Gabarro M, Debrus S, Claire NE, Gray J: A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010, 138:884-897.
• [15]Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al.: Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011, 30:S25-S29.
• [16]Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL: Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010, 28:754-758.
• [17]Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD: Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201:1617-1624.
• [18]Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al.: Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009, 191:157-160.
• [19]Paulke-Korinek M, Kundi M, Rendi-Wagner P, de MA, Eder G, Schmidle-Loss B, et al.: Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29:2791-2796.
• [20]Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al.: Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006–2009. Clin Infect Dis 2011, 53:245-253.
• [21]Parashar UD, Alexander JP, Glass RI: Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-13.